Managing diabetes with insulin can be daunting, especially when faced with similar products. If your doctor has prescribed Lantus or mentioned Semglee, you might wonder what sets them apart.
Semglee is an interchangeable biosimilar to Lantus, meaning it works the same way and can be substituted by your pharmacist without your doctor’s approval. Both contain insulin glargine, a long-acting insulin controlling blood sugar for up to 24 hours.
The main difference is in their manufacturing and regulation—not their performance in your body.
This guide breaks down how these insulins work, what “biosimilar” and “interchangeable” mean, their effectiveness and safety, available devices, cost considerations, and which might suit your needs best.
What Are Semglee and Lantus?
Both medications are long-acting insulins containing insulin glargine, used to manage blood sugar in people with diabetes. Semglee is an FDA-approved interchangeable biosimilar to Lantus, meaning the two work nearly identically in the body.
Overview of Insulin Glargine
Insulin glargine is a synthetic form of human insulin that regulates blood sugar throughout the day. This long-acting insulin maintains steady levels in the bloodstream for about 24 hours after injection.
Lantus contains insulin glargine in its original formulation. Semglee contains insulin glargine-yfgn, which has a slightly different chemical structure.
The main difference is in production: Lantus is derived from bacteria, while Semglee comes from yeast.
Both are administered as subcutaneous injections once daily. They come in 10 mL multi-dose vials or 3 mL prefilled pens (Lantus SoloStar for Lantus, standard pen for Semglee).
Insulin glargine in both products helps cells absorb glucose, preventing dangerous blood sugar spikes.
FDA Approval and Indications
Semglee and Lantus share identical FDA-approved uses for diabetes treatment. Both are indicated to improve glycemic control in adults and children with Type 1 diabetes, and in adults with Type 2 diabetes.
Semglee received interchangeable biosimilar status from the FDA in July 2021, allowing pharmacists to substitute it for Lantus without contacting the prescriber.
Type 1 diabetes patients require insulin because their bodies don’t produce it naturally. Type 2 diabetes patients may need insulin when other treatments fail to control blood sugar.
Both medications are recommended as part of comprehensive diabetes management plans, including diet, exercise, and blood glucose monitoring.
How Semglee and Lantus Work
Both medications function as long-acting insulin analogs, providing steady glucose control throughout the day. They serve as synthetic replacements for the body’s natural baseline insulin production.
Mechanism of Action
Semglee and Lantus both contain insulin glargine, engineered to mimic natural basal insulin. After subcutaneous injection, they form microprecipitates under the skin, slowly releasing insulin into the bloodstream.
The insulin glargine molecule binds to insulin receptors on cells, triggering glucose uptake into muscle and fat cells while suppressing glucose production in the liver.
Lantus uses bacteria-derived insulin glargine, while Semglee uses yeast-derived insulin glargine-yfgn. Despite this, both versions produce clinically identical effects. The slight structural variation does not impact how the insulin regulates blood sugar.
Role as Basal Insulin
Both medications are classified as basal insulin, providing continuous, background insulin coverage. This is different from rapid-acting insulins taken at mealtimes.
Basal insulin addresses the body’s constant need for insulin between meals and overnight. For Type 1 diabetes, it replaces what the pancreas no longer produces. For Type 2 diabetes, it supplements inadequate insulin production.
Both medications take 1-2 hours to begin working. Lantus maintains effectiveness for 20-36 hours, depending on the dose. Semglee typically lasts up to 24 hours. Both are administered once daily at the same time to ensure stable insulin levels.
Biosimilars and Interchangeability Explained
Biosimilar insulin products like Semglee are a newer class of medications closely matching their reference biologics. The FDA’s interchangeability designation allows automatic pharmacy substitution, impacting patients and providers.
What Is a Biosimilar?
A biosimilar is a biologic product highly similar to an already-approved reference biologic. Unlike generic drugs, biosimilars cannot be exact copies because biologics are produced from living organisms.
Semglee (insulin glargine-yfgn) is a biosimilar to Lantus (insulin glargine). Lantus is produced using bacteria; Semglee is derived from yeast.
Biosimilar insulins must demonstrate similar safety, purity, potency, and efficacy compared to the reference product. The FDA requires extensive testing to confirm that biosimilars work essentially the same as their reference products.
Interchangeable Biosimilars and the FDA
An interchangeable biosimilar meets additional FDA requirements, proving that switching between the reference product and biosimilar produces the same clinical results.
Semglee became the first interchangeable biosimilar insulin in July 2021. This means pharmacists can substitute Semglee for Lantus without contacting the prescriber. Regular biosimilars do not have this automatic substitution authority.
The FDA requires specific switching studies for interchangeability. The INSTRIDE 3 trial showed that patients with type 1 diabetes who switched between Lantus and Semglee maintained stable blood sugar control.
This designation gave Semglee 12 months of exclusivity as the only interchangeable biosimilar to Lantus. Prescription data showed rapid increases in Semglee usage after approval.
Other Insulin Glargine Biosimilars
Other insulin glargine biosimilars include Rezvoglar (insulin glargine-aglr), which received interchangeable biosimilar status in December 2021. Basaglar is another biosimilar but lacks interchangeable status.
The development code MYL-1501D refers to Semglee during clinical trials. Each biosimilar undergoes years of testing before reaching patients.
Multiple biosimilar options for insulin glargine now exist, increasing competition and potentially lowering costs. Only Semglee and Rezvoglar currently hold interchangeable designations from the FDA.
Efficacy and Safety Comparison
Clinical trials show Semglee and Lantus deliver comparable efficacy in managing blood glucose, with similar safety profiles in both type 1 and type 2 diabetes. Both insulins show equivalent rates of hypoglycemia and minimal differences in antibody formation.
Effectiveness in Blood Sugar Control
Semglee performs as well as Lantus in controlling blood sugar. The INSTRIDE clinical trials compared the two insulins directly.
Patients using Semglee achieved the same A1C reductions as those using Lantus. The primary measure was changes in A1C levels from baseline to week 24, with Semglee proving noninferior to Lantus.
Key findings:
- A1C changes were statistically equivalent
- Fasting plasma glucose improved similarly
- Insulin dose requirements were comparable
- Self-monitored blood glucose readings showed no meaningful differences
Semglee met the noninferiority margin for A1C changes, confirming its effectiveness matches Lantus.
Glycemic Control in Type 1 and Type 2 Diabetes
Consistent results were seen across diabetes types. INSTRIDE 1 enrolled 558 type 1 diabetes patients who received Semglee or Lantus for 52 weeks, with both groups showing similar glycemic control and hypoglycemic event rates.
Type 2 diabetes patients in INSTRIDE 2 had comparable outcomes. Blood sugar control remained stable when patients switched from Lantus to Semglee, with no adjustment period needed.
INSTRIDE 3 specifically tested switching patients from Lantus to Semglee mid-study, mimicking real-world practice. The switch caused no disruption in diabetes management or glucose control.
Immunogenicity and Antibody Responses
Both insulins produce similar immune responses. Clinical trials monitored antibody formation, finding comparable frequencies of anti-insulin antibodies between Semglee and Lantus groups.
Most antibodies detected were low-titer and did not affect blood glucose control. Post-marketing surveillance has identified some safety signals for both products, but these require further study.
The FDA’s interchangeable designation required proof that switching between the products does not increase immunogenicity risks.
Side Effects and Risks
Semglee and Lantus share nearly identical side effect profiles due to their common active ingredient, insulin glargine. The most common risks include low blood sugar, injection site reactions, and metabolic changes like weight gain.
Hypoglycemia and Low Blood Sugar
Hypoglycemia is the most significant risk with both Semglee and Lantus. This occurs when blood sugar drops below 70 mg/dL.
Common symptoms include shakiness, sweating, rapid heartbeat, dizziness, confusion, irritability, and hunger. Severe hypoglycemia can cause seizures or loss of consciousness if untreated.
The risk increases with skipped meals, extra exercise, or excessive insulin. Both medications’ effects can last up to 36 hours, extending the risk throughout the day and night.
Patients should carry fast-acting carbohydrates like glucose tablets or juice. Hypokalemia (low potassium) can also occur, especially in patients with kidney issues or those taking certain medications.
Injection Site Reactions
Injection site problems, such as redness, swelling, and itching, are common with Semglee and Lantus.
Lipodystrophy—a condition causing abnormal fat distribution under the skin—can develop with repeated injections in the same spot. Post-marketing data show Semglee had higher reports of lipodystrophy compared to other adverse events.
Rotating injection sites helps prevent these issues. Patients should use different areas within the same body region rather than injecting in the exact same spot each time.
Weight Gain, Edema, and Other Effects
Weight gain is common with both insulins because they promote glucose storage in cells. Patients typically gain 2-4 pounds during the first months of treatment.
Edema—fluid retention—can cause swelling in the ankles and legs. This usually resolves on its own but may need medical attention if severe.
Allergic reactions are rare but possible. Symptoms include widespread rash, difficulty breathing, and rapid swelling of the face or throat.
Patients with type 1 diabetes risk diabetic ketoacidosis if they miss doses or take too little insulin. This life-threatening condition requires immediate emergency care.
Forms, Devices, and Dosing
Both medications are available in vials and prefilled pens. Dosing is tailored to each patient’s blood sugar control needs.
The delivery devices differ slightly in branding, but the formulations are bioequivalent.
Prefilled Pens and Vials
Semglee comes in a 10 mL multi-dose vial and a 3 mL prefilled pen. Lantus offers a similar 10 mL vial and the Lantus SoloStar 3 mL pen.
Vials require separate syringes for injection. Prefilled pens offer greater convenience, especially for those injecting insulin outside the home.
Each pen contains 100 units/mL of insulin glargine. Healthcare providers often prescribe pens for patients who prefer simpler dosing.
Pens are pre-loaded and ready to dial to the prescribed dose. Insurance coverage can affect which format is more accessible.
Insulin Pens and Administration
Insulin pens deliver subcutaneous injections once daily at the same time each day. Both the Lantus SoloStar and Semglee pens have dial mechanisms for precise dosing.
Pens should never be shared, even with a new needle, due to infection risk. Standard pen needles attach to the device tip.
Rotating injection sites helps prevent lipodystrophy. Common sites include the abdomen, thighs, and upper arms.
Prefilled pens make self-administration straightforward after initial training by a healthcare provider.
Dosage Individualization
Dosing varies based on diabetes type, body weight, diet, and activity level. Providers start with conservative doses and adjust based on blood glucose monitoring.
Type 1 diabetes patients typically require basal insulin plus rapid-acting mealtime insulin. Type 2 diabetes patients may use Semglee or Lantus alone or with oral medications.
Doses can range from 10 units to over 100 units daily. Exercise, illness, or dietary changes may require dose modifications.
Patients should work closely with providers to find the optimal dose. Never adjust insulin without medical guidance, as incorrect dosing can cause dangerous hypoglycemia or poor glucose control.
Cost, Insurance, and Access
Semglee usually costs about 65% less than Lantus at list price. Actual out-of-pocket costs depend on insurance coverage.
Insurance plans increasingly cover Semglee as a preferred alternative, boosting its adoption.
Pricing Differences
Semglee’s list price is $147.98 for five 3 mL pre-filled pens or $98.65 for one 10 mL vial. Lantus is significantly more expensive.
| Medication | 5 Pens (3 mL) | 1 Vial (10 mL) |
|---|---|---|
| Semglee | $147.98 | $98.65 |
| Lantus | ~$450 | ~$300 |
List prices don’t reflect actual patient costs, which vary by insurance, rebates, and pharmacy discounts. Some insured patients pay similar copays for either medication.
Mylan offers assistance programs for Semglee. Their copay card provides up to $75 off each 30-day prescription for those with commercial insurance.
Uninsured individuals may qualify for free medication through the patient assistance program at (800)796-9526.
Insurance Coverage and Affordability
Insurance coverage determines if you benefit from Semglee’s lower price. Research shows improved insurance coverage drives Semglee adoption more than its biosimilar status.
Many plans now list Semglee as a preferred medication, resulting in lower copays and easier approval. Some plans require prior authorization for Lantus but not for Semglee.
Pharmacists can substitute Semglee for Lantus in most states without contacting your doctor, but your insurance must cover Semglee for you to save money. Always check your plan’s formulary before assuming you’ll pay less.
Who Should Choose Semglee or Lantus?
Semglee and Lantus both contain insulin glargine and work identically for blood sugar management. The choice usually depends on cost and availability, not medical differences.
Patients with Type 1 Diabetes
People with type 1 diabetes need insulin replacement because their bodies produce little or none naturally. Both Semglee and Lantus provide steady 24-hour basal coverage.
Either medication works equally well for type 1 diabetes. Semglee’s FDA approval as an interchangeable biosimilar allows pharmacists to substitute it for Lantus, usually at a much lower cost.
The administration schedule is the same: one daily subcutaneous injection at the same time each day. Neither insulin should be diluted or mixed with other types. Dosing is determined by your provider based on individual needs.
Patients with Type 2 Diabetes
Type 2 diabetes patients often start with oral medications but may need insulin as their condition progresses. Both Semglee and Lantus are FDA-approved for type 2 diabetes.
The decision between the two is typically based on cost and insurance coverage, not efficacy. Type 2 patients often manage multiple medications, making affordability key.
Doctors may prescribe basal insulin alone or with rapid-acting insulin or oral medications. Semglee’s interchangeability means pharmacies can switch patients automatically, potentially saving hundreds of dollars each year.
Special Cases: Gestational Diabetes and Children
Gestational diabetes requires careful management during pregnancy. Insulin glargine has been used in pregnancy, but providers evaluate each case individually.
Children with diabetes can use both Semglee and Lantus, though age restrictions may apply depending on the formulation. Pediatric dosing should be discussed with an endocrinologist.
Pregnant women and parents should consult their healthcare team before switching medications. Providers may want to monitor blood sugar during transitions. Insurance coverage and pharmacy availability can vary, so verify benefits before making changes.
Drug Interactions and Clinical Considerations
Semglee and Lantus interact with 407 medications in identical ways, including 16 major and 363 moderate interactions. It’s important to consider how these insulins work with other diabetes medications, alcohol, and delivery systems.
Interactions With Other Antidiabetic Agents
Combining Semglee or Lantus with other antidiabetic drugs can cause blood sugar to drop lower than with either drug alone. Dose adjustments may be necessary.
Oral medications like metformin, sulfonylureas, and SGLT2 inhibitors increase the risk of hypoglycemia when paired with insulin glargine. Sulfonylureas, in particular, can significantly lower blood sugar.
Common combinations requiring monitoring:
- GLP-1 receptor agonists (reduce insulin doses by 20-30%)
- DPP-4 inhibitors (mild interaction, monitor closely)
- Thiazolidinediones (watch for fluid retention)
- Alpha-glucosidase inhibitors (minimal interaction risk)
Some drugs reduce insulin effectiveness. Corticosteroids, thyroid hormones, and certain psychiatric medications may require higher insulin doses.
Alcohol and Medication Safety
Alcohol affects blood glucose unpredictably with both Semglee and Lantus. Moderate to heavy drinking can trigger delayed hypoglycemia 8-12 hours after consumption.
The liver prioritizes alcohol metabolism over glucose production, creating a risk of sudden blood sugar drops. Limit alcohol to one drink for women and two for men, always with food.
Symptoms of alcohol-induced hypoglycemia mimic intoxication: confusion, drowsiness, and poor coordination can signal dangerously low blood sugar.
Other Insulin Types and Pumps
Rapid-acting insulins like Humalog (insulin lispro) and NovoLog are used with Semglee or Lantus in basal-bolus regimens. The long-acting insulin provides background coverage, while rapid-acting types manage mealtime spikes.
Neither Semglee nor Lantus is suitable for insulin pumps. Pumps require only short-acting or rapid-acting formulations because they deliver continuous micro-doses.
Using insulin glargine in a pump can cause crystallization and lead to pump failure.
Key differences between insulin types:
- Rapid-acting (Humalog, Novolog): 15-minute onset, 4-hour duration
- Short-acting (Regular): 30-minute onset, 6-8-hour duration
- Long-acting (Semglee, Lantus): 1-2-hour onset, 20-36-hour duration
Doses must be adjusted when switching regimens or adding rapid-acting insulin to a long-acting base. Typically, the basal insulin dose is reduced by 20% to avoid stacking effects.
